TearLab Corporation announced the appointment of Wes Brazell as its chief financial officer, with overall responsibility for operational finance, financial reporting, budgeting and strategic planning, as well as helping to manage the company's relationships and interactions with the investment community, according to a company news release. Mr. Brazell succeeds William Dumencu, who will continue to support the company in a consulting role until the end of 2015.
Mr. Brazell has an accomplished history of financial leadership success. In an executive management career that spans close to 3 decades, he most recently served as the chief financial officer of Academic Partnerships, a leader in partnering with universities to increase access to and affordability of higher education through technology and online instruction. Previously, his 21 years of progressive experience at Alcon Laboratories included executive roles as vice president, Global Business Planning and Analysis, chief financial officer (Europe, Middle East and Africa Region) and chief financial officer (United States Region), in addition to earlier positions in commercial finance, internal audit, and investor relations. Before joining Alcon in 1993, Mr. Brazell held various positions at KPMG Peat Marwick, including serving audit clients in the health care, manufacturing and financial sectors as well as training staff accountants in auditing, reporting, and leadership. Mr. Brazell is a Certified Public Accountant, holds a Bachelor of Business Administration degree in Accounting from Baylor University and has completed executive leadership training at Harvard Business School.
TearLab also announced that it is moving its corporate headquarters from San Diego to Dallas-Fort Worth. The move will enable better synergy and effectiveness across the full commercial team, which will now be based out of Texas, according to the news release. In addition, TearLab will maintain its presence in the San Diego market for the R&D and manufacturing side of its business.
"I am excited to welcome Wes as a member of our executive team," TearLab's chief executive officer, Elias Vamvakas, said in the news release. "He is extremely well qualified and brings a breadth of relevant financial management experience that will be invaluable as we execute the next stages of our commercial strategy."
Mr. Brazell said, "This is an exciting time to be joining TearLab, and I am very pleased to return to ophthalmology where I have spent most of my professional career. I look forward to contributing to the company's continued success and identifying ways to enhance shareholder value."